Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Total Current Liabilities

All obligations due within one year.

Pulmonx CorporationNASDAQ: LUNG

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities falls 24.2% from a year ago

Total current liabilities stood at $18.91M at the end of Q1 FY2026, down 24.2% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.

Context

  • Total current liabilities amounted to 15.8% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -24.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.91M-5.7% QoQ
Last fiscal yearDec 2025
$20.06M-17.9% YoY
Year agoMar 2025
$24.95M-24.2% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%——
1 year-17.9%——
3-year CAGR+2.7%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
20.06M USD
Year-over-year change
-17.9%
4-year CAGR
+3.4%

Total Current Liabilities vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's Mar 2026 total current liabilities of $18.91M is the 5th highest of the 10 companies compared; the peer median is $18.22M.
  • Its year-over-year change of -24.2% is the 8th highest of 10, against a peer median of -11.9%.
  • Total current liabilities amounts to 15.8% of total assets for LUNG, versus a peer median of 16.8%.
LUNG Competitors Peer median
Total Current Liabilities for LUNG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ASRTAssertio Holdings, Inc.Mar 2026$91.57M -28.9%+10.2%43.3%
VXRTVaxart, Inc.Mar 2026$76.84M -22.0%+69.2%42.7%
IMUXImmunic, Inc.Mar 2026$38.36M +49.9%+32.8%20.2%
TCRXTScan Therapeutics, Inc.Mar 2026$19.97M -33.0%+2.6%9.9%
LUNGPulmonx CorporationMar 2026$18.91M -24.2%+2.7%15.8%
TELATELA Bio, Inc.Jun 2026$18.22M -4.4%+13.2%30.5%
RLMDRelmada Therapeutics, Inc.Mar 2026$12.89M +146.4%-19.8%5.5%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$11.05M -18.4%+34.0%10.3%
HYPRHyperfine, Inc.Mar 2026$10.15M +27.3%+10.0%16.8%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$8.6M -11.9%+1.8%8.9%
Peer median (excluding LUNG) $18.22M-11.9%+10.2%16.8%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents148.48M101.74M83.55M70.91M70.01M
Short-term Investments31.56M39.4M33.56M30.58M0
Net Receivables6.92M9.28M13.02M13.79M12.07M
Inventory16.29M14.56M16.74M16.92M15.85M
Other Current Assets578K521K741K1.39M3.76M
Total Current Assets208M168.95M150.42M136.25M101.68M
Property, Plant & Equipment (Net)12.89M10.5M7.43M21.45M20.25M
Goodwill2.33M2.33M2.33M2.33M2.33M
Intangible Assets277K154K31K00
Long-term Investments10.94M5.92M14.39M00
Tax Assets00000
Other Non-current Assets731K5.81M3.17M2.82M5.03M
Total Non-current Assets27.17M24.72M27.36M26.6M27.61M
Total Assets235.17M193.68M177.78M162.85M129.29M
Account Payables1.58M1.76M1.5M3.83M3.91M
Short-term Debt91K90K2.16M3.18M1.32M
Tax Payables877K646K93K876K0
Deferred Revenue163K120K104K135K18K
Other Current Liabilities4.74M4.97M7.88M6.89M4.98M
Total Current Liabilities17.55M18.49M23.16M24.44M20.06M
Long-term Debt17.32M17.23M35.09M34M36.99M
Deferred Tax Liabilities37K94K114K87K69K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities179K0000
Total Non-current Liabilities24.38M21.18M36.31M52.6M55.12M
Total Liabilities41.93M39.67M59.47M77.04M75.18M
Common Stock37K38K39K40K42K
Retained Earnings(291.4M)(350.32M)(411.16M)(467.56M)(521.56M)
Accumulated OCI1.71M1.58M2.64M2.11M2.36M
Other Stockholders Equity00000
Minority Interest00000
Total Equity193.24M154.01M118.32M85.81M54.12M
Total Debt26.46M24.4M41.42M56.47M56.36M
Net Debt(122.02M)(77.33M)(42.12M)(14.43M)(13.65M)

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.